• Downloads
  • Contact Us
  • Directions
  • Deutsch Deutsch German de
  • English English English en
  • 简体中文 简体中文 Chinese (Simplified) zh-hans
Epitype GmbH
  • Products
  • About us
    • Management
    • Team
    • Research projects
    • Publications
    • Press
    • Jobs
  • Contact
    • Directions
    • Contact Us
  • News / Blog
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu

International sales partnership with EUROIMMUN for Distribution of GynTect

Press Releases
Vertriebspartnerschaft zwischen der oncgnostics GmbH und der EUROIMMUN Medizinische Labordiagnostika AGoncgnostics GmbH Susann Nuernberger / EUROIMMUN Medizinische Labordiagnostika AG

Biotechnology company oncgnostics GmbH is announcing a collaboration with the international diagnostics group EUROIMMUN, a PerkinElmer company. As part of the cooperation, EUROIMMUN will sell the cervical cancer test from oncgnostics GmbH, Gyn-Tect, in the European countries of Portugal, Italy, Turkey and Poland. Also the test is expected to be approved and on sale in Canada by the end of 2021.

The partnership is a valuable addition to the product portfolios of both companies: For seven years, EUROIMMUN has been successfully selling the EUROArray HPV, a molecular genetic test for the detection and complete genotyping of human papilloma viruses (HPV). The EUROIMMUN test can detect an HPV infection in women with a very high degree of certainty. However, not every HPV infection leads to a serious illness as most women with an HPV infection remain healthy and the infection heals on its own. Yet, no HPV test can predict this development. At this point the GynTect test developed by oncgnostics GmbH comes in. The innovation of this test enables the reliable detection of DNA methylations, which are only present in the development of cancer cells. Thus, a malignant change that can develop into cancer can be detected by this solution.

“With the addition of GynTect to our product range, EUROIMMUN now has a complete package for cervical cancer diagnostics,” said Dr. Wolfgang Schlumberger, CEO of EUROIMMUN. “The EUROArray HPV helps to estimate the individual cancer risk of patients thanks to the clear identification of 30 HPV subtypes. With GynTect, this risk can now be further specified with an additional step. A negative GynTect test can give many women with a proven HPV infection a sign of relief at an early stage.”

Oncgnostics produces GynTect tests in its own production laboratory in Germany. They are sold internationally through EUROIMMUN to laboratories that carry out and evaluate the tests locally in the various countries.

Additional international cooperations

Beside the first four EU countries and Canada, GynTect will be gradually introduced into other EU markets. “We consider the fight against cervical cancer as a global challenge. In addition to the nationwide vaccination, precise preventive tests play a major role. We are very pleased that this partnership gives us access to the widely developed EUROIMMUN sales network. By making new contacts with laboratories and physicians, more and more women are benefiting from the advantages of GynTect. We are building on this and are looking forward to working together,” says Dr. Martina Schmitz, managing director of oncgnostics GmbH.

 

GynTect is a molecular biological test that detects six areas of the human genome that are only methylated when cancer cells develop. Thus, GynTect recognises malignant changes in patients.

Mehr Informationen

 

About EUROIMMUN Medizinische Labordiagnostika AG:

As one of the world’s leading manufacturers in the field of medical laboratory diagnostics, EUROIMMUN stands for innovation. More than 3,200 employees in 17 countries develop, produce and distribute test systems that can be used for diagnosing diseases, as well as software and automation solutions for applying and evaluating the tests. Laboratories in over 150 countries use EUROIMMUN products to diagnose autoimmune and infectious diseases as well as allergies and to carry out gene analyses. EUROIMMUN has been part of the US company PerkinElmer Inc. since 2018.

For more information, see www.euroimmun.de/en/

25. March 2021/by TowerPR
https://www.epitype.de/wp-content/uploads/2021/03/210315_Vertrag_Euroimmun_Website.jpg 321 845 TowerPR https://www.epitype.de/wp-content/uploads/2025/09/epitype_website-logo-300x130.png TowerPR2021-03-25 09:44:542021-03-25 09:44:54International sales partnership with EUROIMMUN for Distribution of GynTect

PCR: Certainty in the shortest possible time

Blog
Anwendung der PCR-Methode im oncgnostics-Labor

The method of the PCR stands for the polymerase chain reaction. The underlying process has fundamentally changed medical and biotechnological research. It is now considered the most important laboratory method for investigating the molecular structure of our genetic material (= DNA). This is partly due to the fact that the PCR analysis is versatile. It is used in all oncgnostics projects and is an elementary part of our GynTect test for cervical cancer. However, the PCR test recently gained publicity through its use in the current worldwide testing of Corona.

What is PCR used for?

Laboratories use the methodology for amplifying DNA in the shortest possible time. Quick runs, so-called Fast-PCRs, take place within 10 minutes. Others last between one and two hours.

Take our cervical cancer test GynTect: The aim of the PCR is to find out whether certain, epigenetically modified gene sequences that only occur in cancer cells, are present. These are known as methylation of DNA.

In order to clarify this question via PCR based diagnosis, you need the following:

  • DNA from the sample to be examined. The sample is taken at the gynecological practice where the affected woman is cared for.
  • Nucleotides: These are the basic chemical building blocks of DNA which are needed to make copies of the given DNA strand.
  • Polymerases: This is a class of enzymes that is essential for the replication of DNA.
  • Specific primers: The artificially generated, short oligonucleotide chains serve as starting molecules for the polymerase. They dock on the DNA strand, marking the point at which the polymerase begins its work. Depending on which regions (= biomarkers) of the DNA are to be detected, other primers serve as keys for the PCR method.
  • Finally, a buffer solution is needed in which the reaction runs and which keeps the pH during the reaction stable.

Polymerase chain reaction: Process in the thermal cycler

The replication of the DNA usually takes place in three steps in a so-called thermal cycler. This laboratory device regulates the exact temperatures during the biochemical reaction.

  1. The first step is denaturation. The sample is heated to 94-96 °C. This causes the two strands of the double-stranded DNA to separate from one another.
  2. For the second phase of primer hybridization, the sample is rapidly cooled down to 50-65 °C. The respective temperature depends on the primers used, which serve as specific keys as described above. The primers now dock at the suitable points on the two single strands of the DNA.
  3. In the final step of elongation, also called extension, the single strands of the DNA become double strands again. The temperature is increased again to 68-72 °C. The polymerase attaches to the small areas of double-stranded DNA that were created by the primers. With the help of the loose nucleotides, it completes the double strand.

In the last phase, around 500 base pairs are formed within 30 seconds. The length of the third step depends on the length of the DNA sequence to be examined. Once the third step is completed, a new PCR cycle starts. As a result, the DNA amount in the areas of the markers to be detected increases exponentially. More than one billion copies can be available after just 30 cycles. The entire process usually takes one hour.

Important: The DNA sample is only duplicated if it contains the gene sequence you are looking for. In the case of GynTect or Corona, the DNA sample would be positive in this case.

PCR for diagnostics: What happens when using GynTect?

When performing GynTect, we use the described procedure. If there is a methylation of DNA for the corresponding gene sequence, which occurs exclusively in cancer cells and cancer precursor cells, the DNA can be replicated using specific GynTect primers. The result is positive. In this case, the sample lights up.

A specific fluorescent dye is applied for the optical signal. In successive cycles, this is repeatedly stored in double-stranded pieces of DNA that the PCR generates. The more duplicated DNA there is, the stronger the light signal. The cycle from which the resulting luminous signal significantly exceeds the background light is called the Cycle threshold, also known as Ct. For the GynTect test, a certain amount of DNA methylation data is at least necessary for a sample to be recognized as positive. However, the proportion is less than one percent. For Corona PCR tests, some few viruses in a sample are required to yield a positive result. The lower the Ct value, the more viruses were present in the original sample.

If the sample is negative, no methylation of DNA is detected. In this case, the PCR does not generate any DNA fragments and the dye is not stored anywhere. Accordingly, the sample does not emit a light signal.

You can see the preparation of the PCR for GynTect in this video.

Advantage and history of the PCR analysis

The advantage clearly lies in its ease of use. The tool proves specific genetic information in an uncomplicated and targeted manner. Here it is key that the primers specifically recognize the target sequence. In the example of GynTect, we apply primers that only fit certain, in this case six different, gene regions, and the primers only fit if the regions were previously methylated.

Research into the diagnostic method dates back to the 1950s. In its present sense, it was invented in 1983 and only 10 years later, in 1993, it was awarded the Nobel Prize for Chemistry. Today, many different PCR thermal cyclers are used in most laboratories.

24. March 2021/by TowerPR
https://www.epitype.de/wp-content/uploads/2021/03/1506_Blogbeitrag_PCR.jpg 321 845 TowerPR https://www.epitype.de/wp-content/uploads/2025/09/epitype_website-logo-300x130.png TowerPR2021-03-24 16:11:232021-03-24 16:11:23PCR: Certainty in the shortest possible time

Archive

Recent Posts

  • Worldwide unique test for cervical cancer as a gamechanger for the healthcare system
  • Jena Biotechnology Company Files for Insolvency
  • Bachelor thesis in biotechnology companies: From research to diagnostics 

Epitype GmbH

The Epitype GmbH, a spin-off of the University Hospital Jena, is a company working on molecular diagnostics with main focus on the development of in-vitro diagnostics based on epigenetic biomarkers.

Epitype GmbH is working according to ISO 13485 standards in research, development, production and management.

Recent Posts

  • Worldwide unique test for cervical cancer as a gamechanger for the healthcare system
  • Jena Biotechnology Company Files for Insolvency
  • Bachelor thesis in biotechnology companies: From research to diagnostics 

Contact

Epitype GmbH
Löbstedter Str. 41
07749 Jena
Germany

Phone: +49 (0)3641 5548500

Email: contact[at]epitype.de
Internet: www.epitype.de

© 2015 - 2025 Epitype GmbH Jena Germany
  • Start
  • Imprint
  • Contact Us
  • Privacy policy
Scroll to top

Cookies help us deliver our services. By using our services, you agree to our use of cookies.

Learn moreI accept

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Privacy policy
Einstellungen akzeptierenVerberge nur die Benachrichtigung
Epitype GmbH
Einwilligung verwalten

Um Ihnen ein optimales Erlebnis zu bieten, verwenden wir Technologien wie Cookies, um Geräteinformationen zu speichern und/oder darauf zuzugreifen. Wenn Sie diesen Technologien zustimmen, können wir Daten wie das Surfverhalten oder eindeutige IDs auf dieser Website verarbeiten. Wenn Sie Ihre Einwilligung nicht erteilen oder zurückziehen, können bestimmte Merkmale und Funktionen beeinträchtigt werden.

Funktional Always active
Die technische Speicherung oder der Zugang ist unbedingt erforderlich für den rechtmäßigen Zweck, die Nutzung eines bestimmten Dienstes zu ermöglichen, der vom Teilnehmer oder Nutzer ausdrücklich gewünscht wird, oder für den alleinigen Zweck, die Übertragung einer Nachricht über ein elektronisches Kommunikationsnetz durchzuführen.
Präferenzen
Die technische Speicherung oder der Zugriff ist für den rechtmäßigen Zweck der Speicherung von Präferenzen erforderlich, die nicht vom Abonnenten oder Benutzer angefordert wurden.
Statistiken
Die technische Speicherung oder der Zugriff, der ausschließlich zu statistischen Zwecken erfolgt. Die technische Speicherung oder der Zugriff, der ausschließlich zu anonymen statistischen Zwecken verwendet wird. Ohne eine Vorladung, die freiwillige Zustimmung deines Internetdienstanbieters oder zusätzliche Aufzeichnungen von Dritten können die zu diesem Zweck gespeicherten oder abgerufenen Informationen allein in der Regel nicht dazu verwendet werden, dich zu identifizieren.
Marketing
Die technische Speicherung oder der Zugriff ist erforderlich, um Nutzerprofile zu erstellen, um Werbung zu versenden oder um den Nutzer auf einer Website oder über mehrere Websites hinweg zu ähnlichen Marketingzwecken zu verfolgen.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
Einstellungen ansehen
  • {title}
  • {title}
  • {title}